PCN103 The Adjuvant Treatment of Stage 3 Colon Cancer (aCC): An Indirect Cost-Minimisation and Population Net Health Benefit Analysis of Capecitabine + Oxaliplatin (XELOX) vs. iv 5-FU + FA + Oxaliplatin (FOLFOX)

Subjects

Subjects :

Oncology
medicine.medical_specialty
education.field_of_study
business.industry
Colorectal cancer
medicine.medical_treatment
Health Policy
Population
Public Health, Environmental and Occupational Health
Health benefits
medicine.disease
Minimisation (clinical trials)
Oxaliplatin
Indirect costs
FOLFOX
Internal medicine
Medicine
business
education
Adjuvant
health care economics and organizations
medicine.drug

Details

ISSN :

10983015

Volume :

14

Issue :

7

Database :

OpenAIRE

Journal :

Value in Health

Accession number :

edsair.doi.dedup.....956277c5a1241a5336d1ef618434a8cc

Full Text :

https://doi.org/10.1016/j.jval.2011.08.1204